Lumora, a UK-based molecular diagnostics developer spun out of University of Cambridge, has sold off its nucleic acid purification platform to pharmaceuticals and diagnostics developer Roche.
Financial terms of the deal have not been disclosed.
Founded in 2004, Lumora claims it has reduced the time isolating necessary nucleic acids such as DNA or RNA for testing.
Roche hopes to integrate the approach into the sequencing process it uses for research purposes.
Lumora had raised $8.91m in total before the deal,…
